Case report: A rare case of renal epithelioid angiosarcoma

Jiancheng Zhai, Bangwei Che, Jun Shen, Kefa Cen, Yusui Zhang, T Y Li, Dongxin Tang, Kaifa TangFrontiers in Oncology 2024 · DOI

TL;DR

This paper documents an exceptionally rare case of primary renal epithelioid angiosarcoma (EAS) in an 81-year-old patient, marking only the seventh such case reported in medical literature. The authors highlight how specific immunohistochemical markers and "speckled" calcifications on CT scans can help clinicians distinguish this aggressive malignancy from more common renal cancers.

What Problem Does This Paper Address?

Primary renal epithelioid angiosarcoma is a "diagnostic chameleon." It is a highly aggressive soft tissue sarcoma originating from endothelial cells that rarely presents in the kidney. Because it is so uncommon, it is frequently misdiagnosed as more typical renal malignancies, such as clear cell renal cell carcinoma (ccRCC) or epithelioid angiomyolipoma (EAML).

The challenge for clinicians is that EAS lacks specific clinical symptoms—usually presenting with common issues like hematuria or flank pain—and its imaging features often overlap with other tumors. This paper aims to provide a detailed clinical, radiological, and pathological roadmap to help specialists identify this rare disease earlier, which is critical given its typically poor prognosis.

Methods

As a clinical case report, the study follows a single patient’s diagnostic and therapeutic journey. The key methodologies employed include:

  • Radiological Imaging: Contrast-enhanced Computerized Tomography (CT) was used to identify the mass and assess metastasis.
  • Surgical Intervention: A laparoscopic palliative nephrectomy was performed to remove the primary tumor.
  • Histopathology: The tumor tissue was examined using standard Hematoxylin and Eosin (H&E) staining at various magnifications to observe cell morphology and vascular structures.
  • Immunohistochemistry (IHC): This was the definitive diagnostic tool. The authors tested for a broad panel of markers, including CD31, CD34, vimentin, CD10, and various cytokeratins (CK), to differentiate the tumor from other sarcomas and carcinomas.

Datasets

While this is a single-patient case report, the authors compiled a comparative dataset in Table 2, summarizing the clinical data, imaging findings, and IHC results of all seven known cases of renal EAS reported to date. This meta-summary serves as a mini-benchmark for the current state of knowledge regarding this specific pathology.

Key Insights and Ideas

  • The "Speckled" Clue: One of the most significant findings was the presence of scattered, speckled calcifications in the center of the mass on CT imaging. While calcifications occur in other renal cancers, the authors suggest this specific pattern might be a helpful radiological marker for EAS.
  • The IHC Profile: The diagnosis was confirmed by a specific protein expression profile: positive for CD31, CD10, and vimentin, but negative for cytokeratins (CK) and other common renal markers like PAX-8. This "positive-negative" signature is essential for ruling out renal cell carcinoma.
  • Morphological Mimicry: Microscopically, the tumor cells displayed "epithelioid" features (polygonal shapes and abundant cytoplasm), which is why it so easily mimics epithelial tumors (carcinomas) under the microscope.
  • Aggressive Nature: Despite surgical intervention, the patient’s condition deteriorated rapidly due to pulmonary complications and advanced age, underscoring the high mortality rate associated with EAS.

Key Results

  • Diagnostic Confirmation: The pathology revealed a 60 x 50 x 50 mm solid, grayish-brown tumor with extensive necrosis.
  • IHC Consistency: The study found that CD31 and Vimentin expression was 100% consistent across the reviewed cases, while CD34 (often considered a standard vascular marker) was only positive in 60% of cases.
  • Literature Review: By comparing their case to the six previously reported ones, the authors noted that renal EAS predominantly affects the elderly (average age in the 60s-80s) and frequently presents with gross hematuria.

Limitations and Future Work

The primary limitation is the extremely small sample size. With only seven cases known globally, it is difficult to establish a "gold standard" for diagnosis or a definitive treatment protocol. The authors acknowledge that while the speckled calcification is a promising diagnostic sign, it requires validation across more cases.

Future work would involve multi-center collaborations to pool data on rare sarcomas, potentially identifying genetic drivers (like the WWTR1-CAMTA1 fusion seen in related vascular tumors) that could lead to targeted therapies rather than relying solely on aggressive surgery and non-specific chemotherapy.

Summary updated

Abstract

Primary renal epithelioid angiosarcoma (EAS) is extremely rare and carries a poor prognosis. Herein, we present a case of renal EAS in an 81-year-old male patient who complained of hematuria for 1 year. A computerized tomography (CT) scan revealed an occupying lesion at the upper pole of the left kidney, with scattered calcifications, along with retroperitoneal lymph node metastasis and possible lung metastasis. A laparoscopic palliative nephrectomy was performed, and postoperative pathology confirmed a malignant tumor with necrosis in the left kidney. Immunohistochemistry (IHC) revealed positive expression for CD31, CD10, and vimentin, consistent with the diagnosis of EAS. Although EAS is a rare, aggressive, and often misdiagnosed condition, IHC can help confirm its diagnosis, and in our case, the scattered calcifications observed on CT imaging might be helpful in its differential diagnosis.
BibTeX
@inproceedings{zhai2024case,
  author = {Jiancheng Zhai and Bangwei Che and Jun Shen and Kefa Cen and Yusui Zhang and T Y Li and Dongxin Tang and Kaifa Tang},
  title = {{Case report: A rare case of renal epithelioid angiosarcoma}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1461165},
}
Figure